FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Investor's Business Daily on MSN52m
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.
Vertex Pharmaceuticals price target raised to $550 from $535 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...
FDA approves new painkiller designed to avoid opioid addiction risk
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Forbes Daily: DeepSeek’s AI Model Raises National Security Concerns
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
WISH-TV50m
Barnes and Noble credits growth to emergence of ‘BookTok’
Discover the latest trends in the business world, from Barnes and Noble's growth fueled by BookTok to the FDA's approval of a new nonopioid pain medication.
Investing53m
Apple, Exxon Mobil, AbbVie rise premarket; Chevron, Colgate-Palmolive fall
AbbVie (NYSE: ABBV) stock rose 4.2% after the drugmaker forecast 2025 profit above estimates, as strong sales of its newer ...